Tier 2 — strong

Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis

Bertuccioli A, Moricoli S, Amatori S, Rocchi MBL, Vici G, Sisti D

Journal of medicinal food 2020 23(2):101-113

Bibliography

PubMed: PMID 31441678
DOI: 10.1089/jmf.2019.0088
Funding: Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests: A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Design	Systematic review and meta-analysis
Model	Published human studies
Sample	19 studies; 12 controlled and 7 cross-sectional
Intervention	Evidence synthesis; interventions and comparators vary across included studies
Duration	No new treatment; included-study durations vary
Endpoints	Pooled clinical or metabolic outcomes; Risk of bias and heterogeneity; Adverse-event reporting

This synthesis examined plain and combination preparations without statin-like components. It reported lipid changes that differed by formulation.

This synthesis examined plain and combination preparations without statin-like components. It reported lipid changes that differed by formulation.

Includes nonrandomized designs and indirect formulation comparisons; cannot establish that one formulation is clinically superior.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Editorial review

Last verified 22 October 2026